Hanna, Michael G
Badrising, Umesh A
Benveniste, Olivier
Lloyd, Thomas E
Needham, Merrilee
Chinoy, Hector
Aoki, Masashi
Machado, Pedro M
Liang, Christina
Reardon, Katrina A
de Visser, Marianne
Ascherman, Dana P
Barohn, Richard J
Dimachkie, Mazen M
Miller, James A L
Kissel, John T
Oskarsson, Björn
Joyce, Nanette C
Van den Bergh, Peter
Baets, Jonathan
De Bleecker, Jan L
Karam, Chafic
David, William S
Mirabella, Massimiliano
Nations, Sharon P
Jung, Hans H
Pegoraro, Elena
Maggi, Lorenzo
Rodolico, Carmelo
Filosto, Massimiliano
Shaibani, Aziz I
Sivakumar, Kumaraswamy
Goyal, Namita A
Mori-Yoshimura, Madoka
Yamashita, Satoshi
Suzuki, Naoki
Katsuno, Masahisa
Murata, Kenya
Nodera, Hiroyuki
Nishino, Ichizo
Romano, Carla D
Williams, Valerie S L
Vissing, John
Auberson, Lixin Zhang
Wu, Min
de Vera, Ana
Papanicolaou, Dimitris A
Amato, Anthony A
Funding for this research was provided by:
Novartis
National Health Insurance Service
Massachusetts General Hospital
UCLH Biomedical Research Centre
Novartis Pharmaceuticals UK Limited
Manchester Biomedical Research Centre (MR/N003322/1)
National Institute for Health and Care Research
Medical Research Council (MR/K000608/1)
This article is maintained by: Elsevier
Article Title: Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial
Journal Title: The Lancet Neurology
CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/S1474-4422(19)30200-5
CrossRef DOI link to the associated document: https://doi.org/10.1016/S1474-4422(19)30279-0
Content Type: article
Copyright: © 2019 Elsevier Ltd. All rights reserved.